Syndax Pharmaceuticals Inc Aktie News

Syndax now has two approved therapies—NIKTIMVO and Revuforj—but the share price remains under pressure despite these milestones. NIKTIMVO faces a crowded cGVHD market and skepticism about its commercial potential, with analysts projecting modest long-term sales. Revuforj offers significant upside, targeting an underserved leukemia niche with minimal competition and potential for label expansion...

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on July 1, 2025 the Company granted inducement awards to purchase up to 228,400 shares of common stock to 14 new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years,...

– PDUFA action date set for October 25, 2025 – – sNDA being reviewed under FDA's RTOR program – – Revumenib has the potential to become the first and only menin inhibitor approved in both R/R mNPM1 AML and R/R KMT2Ar acute leukemia – NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapi...

– Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients –

– 26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population – – Robust responses observed across subgroups, regardless of co-mutations, number of prior lines of therapy, or prior venetoclax, within efficacy-evaluable pivotal R/R mNPM1 AML population – – 60% (3/5) ORR in Ph 1 patients with R/R NUP98r AML – NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Synda...

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on June 1, 2025 the Company granted inducement awards to purchase up to 119,700 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four yea...

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:

– Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r –